Blog

TCR-Mimic Antibody Platform

Immunotherapy has made a great breakthrough in recent years, and antibody therapy is the core of this breakthrough. Traditional antibody therapies target cell membrane surface antigens (such as PD-1 and PD-L1) or soluble antigens. However, ideal tumor antigens (such as…

Keep Reading

Press Releases

Biocytogen Expands Partnership with Merck

Biocytogen Expands Partnership with Merck Beijing, China and Darmstadt, Germany, August 25, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform. Under the terms of the agreement, Merck…

Keep Reading

Press Releases

Biocytogen Enters into Antibody Agreement with Merck

BEIJING, CHINA, [April 29, 2022] – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen’s proprietary antibodies against at least three distinct…

Keep Reading

Press Releases

Biocytogen Signs RenMab™/RenLite® Licensing Agreement with BeiGene

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) reached an agreement with BeiGene (Beijing) Co., Ltd. (“BeiGene”) (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully human antibody RenMab™/RenLite® mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of…

Keep Reading

News

RenMab™ and RenLite® Models Featured in GEN Magazine

In the August issue of Genetic Engineering & Biotechnology News, Biocytogen’s RenMab™ (fully human antibody mouse) and RenLite® (common light chain) models are introduced in the article, as well as a case study using RenMab™ to generate timely monoclonal antibody treatment…

Keep Reading

Press Releases

Biocytogen Closes $79M Series D Funding

Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way…

Keep Reading